GlassScriptPhysician profile
Michael A Wilensky
NPI 1063411478
$2,116.04
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $265 · 2021: $858 · 2022: $587.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $600.51 | 2020-2021 | |
| Horizon Therapeutics Plc | $228.45 | 2022 | |
| Genzyme Corporation | $227.62 | 2019-2022 | |
| Abbvie INC. | $188.13 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $155.25 | 2019-2021 | |
| Biogen, INC. | $137.76 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $128.43 | 2022 | |
| Boston Scientific Corporation | $110.99 | 2019 | |
| Genentech USA, INC. | $104.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $65.88 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $49.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $47.52 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $38.82 | 2021 | |
| Amgen INC. | $19.83 | 2021 | |
| Allergan, INC. | $12.75 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilensky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.